Copyright
©The Author(s) 2021.
World J Gastroenterol. Nov 28, 2021; 27(44): 7661-7668
Published online Nov 28, 2021. doi: 10.3748/wjg.v27.i44.7661
Published online Nov 28, 2021. doi: 10.3748/wjg.v27.i44.7661
Ref. | Yr | Country | Study type | Treatment details | n | Success rate (PP, %) | Success rate (ITT, %) |
Prach et al[10] | 1998 | United Kingdom | Prospective,single cohort | 1st line O 20 mg b.d., C 500 mg t.d.s, 14 ds | 3 | 100; | 100; |
Gisbert et al[11] | 2005 | Spain | Prospective, single cohort | 1st line O 20 mg b.d., C 500 mg b.d., M 400 mg b.d., 7 d; 2nd line RBC 400 mg b.d., T 500 mg q.d.s., M 250 mg q.d.s., 7 d; 3rd line O 20 mg b.d., C 500 mg b.d., RIF 150 mg b.d., 10 d; 4th line O 20 mg b.d., C 500 mg b.d., LF 500 mg b.d.,10 ds | 12; 17; 9; 2 | 64; 53; 17; 100 | 58; 47; 11; 100 |
Rodriguez-Torres et al[12] | 2005 | Puerto Rico | Prospective, single cohort | 1st line E 40 mg q.d.s., T 500 mg q.d.s., M 500 mg q.d.s.,10 d; 2nd line E 40 mg q.d.s., T 500 mg q.d.s., M 500 mg q.d.s.,10 d | 17; 3 | NA; NA | 85; 100 |
Matsushima et al[13] | 2006 | Japan | Retrospective, single cohort | 1st line PPI o.d., T 500 mg b.d., M 250 mg b.d., 7-14 d | 5 | 100 | 80 |
Gisbert et al[14] | 2010 | Spain | Prospective, single cohort | 1st line O 20 mg b.d., C 500 mg b.d., M 400 mg b.d., 7 d; 2nd line O 20 mg b.d., C 500 mg b.d., LF 500 mg b.d.,10 d | 50; 15 | 55; 73 | 54; 73 |
Tay et al[15] | 2012 | Australia | Prospective, single cohort | 2nd line R 20 mg t.d.s., B 240 mg q.d.s., RIF 150 mg b.d., CF 500 mg b.d., 10 d | 69 | 94.2 | 94.2 |
Liang et al[16] | 2013 | China | Prospective, randomised | 2nd line 109 pen allergic overall but results reported for whole group including non-allergic; L 30 mg b.d., B 220 mg b.d., T 500 mg t.d.s., F 100 mg t.d.s., 14 d; L 30 mg b.d., B 220 mg b.d., T 500 mg q.d.s., M 400 mg q.d.s., 14 d | 108; 107 | 96.1; 93.1 | 91.7; 87.9 |
Furuta et al[17] | 2014 | Japan | Retrospective, single cohort | 1st line PPI b.d., SF 100 mg b.d., M 250 mg b.d., 7 d; 1st line PPI b.d., SF 100 mg b.d., M 250 mg b.d., 14 d; 2nd Line PPI b.d., SF 100 mg b.d., M 250 mg b.d., 7 d; 2nd Line PPI b.d., SF 100 mg b.d., M 250 mg b.d., 14 d; 3rd Line PPI b.d., SF 100 mg b.d., M 250 mg b.d., 7 d; 3rd Line PPI b.d., SF 100 mg b.d., M 250 mg b.d., 14 d | 7; 4; 9; 3; 3; 2 | 100; 100; 100; 100; 100; 100 | 100; 100; 100; 100; 100; 100 |
Gisbert et al[18] | 2015 | Spain | Prospective, single cohort | 1st line O 20 mg b.d., C 500 mg b.d., M 400 mg b.d., 7 d; 2nd line O 20 mg b.d., B 120 mg q.d.s., T 500 mg q.d.s., M 500 mg t.d.s., 10 d; 3rd line O 20 mg b.d., C 500 mg b.d., LF 500 mg b.d.,10 d; 4th line O 20 mg b.d., C 500 mg b.d., RIF 150 mg b.d., 10 d; 3rd line O 20 mg b.d., C 500 mg b.d., RIF 150 mg b.d., 10 d; 4th line O 20 mg b.d., C 500 mg b.d., LF 500 mg b.d.,10 d; 2nd line O 20 mg b.d., C 500 mg b.d., LF 500 mg b.d.,10 d; 3rd line O 20 mg b.d., B 120 mg q.d.s., T 500 mg q.d.s., M 500 mg t.d.s., 10 d; 1st line O 20 mg b.d., B 120 mg q.d.s., T 500 mg q.d.s., M 500 mg t.d.s., 10 d; 2nd line O 20 mg b.d., C 500 mg b.d., LF 500 mg b.d.,10 d | 112; 24; 3; 2; 7; 2; 50; 3; 50; 14 | 59; 38; 50; 0; 20; 100; 73; 100; 75; 64; | 57; 37; 33; 50; 14; 100; 64; 100; 74; 64; |
Mori et al[19] | 2017 | Japan | Prospective, single cohort | 1st line E 20 mg b.d., SF 100 mg b.d., M 250 mg b.d.,10 d; 2nd line E 20 mg b.d., SF 100 mg b.d., M 250 mg b.d.,10 d; 3rd line E 20 mg b.d., SF 100 mg b.d., M 250 mg b.d.,10 d | 33; 19; 5 | 100; 84.2; 40 | 100; 84.2; 40 |
Ono et al[20] | 2017 | Japan | Retrospective,single cohort | 1st line PPI b.d., C 200 mg b.d., M 250 mg b.d., 7 d; 1st line V 20 mg b.d., C 200 mg b.d., M 250 mg b.d., 7 d; 1st line PPI b.d., SF 100 mg b.d., M 250 mg b.d., 7 d; 1st line V 20 mg b.d., SF 100 mg b.d., M 250 mg b.d., 7 d; 2nd line PPI b.d., C 200 mg b.d., M 250 mg b.d., 7 d; 2nd line V 20 mg b.d., C 200 mg b.d., M 250 mg b.d., 7 d; 2nd line PPI b.d., SF 100 mg b.d., M 250 mg b.d., 7 d; 2nd line V 20 mg b.d., SF 100 mg b.d., M 250 mg b.d., 7 d | 10; 13; 20; 14; 3; 1; 24; 3 | 55.6; 92.3; 100; 100; 33.3; 100; 100; 66.7 | 50; 92.3; 100; 92.9; 33.3; 100; 100; 66.7 |
Sue et al[21] | 2017 | Japan | Prospective& retrospective, single cohort | 1st line V 20 mg b.d., C 200 or 400 mg b.d., M 250 mg b.d., 7 d; 1st line PPI b.d, C 200 or 400 mg b.d, M 750 mg b.d., 7 d | 20; 30 | 100; 86.2 | 100; 83.3 |
Osumi et al[22] | 2017 | Japan | Prospective, single cohort | 1st line R 20 mg b.d, Mi 100 mg b.d, M 250 mg b.d., 7 d | 5 | 100 | 100 |
Long et al[23] | 2018 | China | Prospective, randomised | 1st line E 20 mg b.d., C 500 mg b.d., M 400 mg b.d., 14 d; 1st line E 20 mg b.d., B 600 mg b.d., C 500 mg b.d., M 400 mg b.d., 14 d | 33; 33 | 70; 96 | 63.6; 84.8 |
Song et al[24] | 2019 | China | Prospective, single cohort | 1st line E 20 mg b.d, B 220 mg b.d., LF 500 mg o.d., Cef 500 mg b.d., 14 d | 152 | 90.1 | 85.5 |
Nyssen et al[25] | 2020 | Europe | Retrospective,multi-centre registry | 1st line PPI, C, M; 1st line PPI, C, LF; 1st line PPI, B, T, M; 2nd line PPI, C, LF; 2nd line PPI, M, LF; 2nd line PPI, B, T, M; 3rd line PPI, B, T, M; 3rd line PPI, B, C, LF; 3rd line PPI, C, LF (NB drug dose, frequency and duration not specified) | 285; 54; 250; 20; 13; 70; 18; 1; 2 | 69; 82; 92; 73.7; 76.5; 81.8; 77.8; 100; 50 | 69; 80; 91; 75; 76.5; 78.3; 77.8; 100; 50 |
Luo et al[26] | 2020 | China | Prospective, single cohort | 1st & 2nd line E 20 mg b.d., C 500 mg b.d., M 400 mg b.d., 14 d; 1st & 2nd line E20 mg b.d., B 220 mg b.d., C 500 mg b.d., M 400 mg q.d.s., 14 d; 1st & 2nd line E 20 mg b.d., LF 500 mg o.d., M 400 mg b.d., 14 d; 1st & 2nd line E 20 mg b.d., B 220 mg b.d, LF 500 mg o.d., M 400 mg q.d.s., 14 d; 1st & 2nd line E 20 mg b.d., T 500 mg q.d.s., M 400 mg b.d., 14 d; 1st & 2nd line E 20 mg b.d., B 220 mg b.d, T 500 mg q.d.s., M 400 mg q.d.s., 14 d | 5; 22; 1; 10; 2; 72 | 100; 94.1; 100; 100; 100; 100 | 100; 81.8; 100; 80; 100; 97.2 |
Sue et al[27] | 2021 | Japan | Prospective, single cohort | 2nd line V 20 mg b.d,, SF 100 mg b.d., M 250 mg b.d., 7 d | 17 | 88.2 | 88.2 |
- Citation: Dutta AK, Phull PS. Treatment of Helicobacter pylori infection in the presence of penicillin allergy. World J Gastroenterol 2021; 27(44): 7661-7668
- URL: https://www.wjgnet.com/1007-9327/full/v27/i44/7661.htm
- DOI: https://dx.doi.org/10.3748/wjg.v27.i44.7661